Biocryst Pharma Inc (BCRX) 3.05 $BCRX BioCryst to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 4:14 PM

Biocryst Pharma Inc (BCRX) 3.05 $BCRX

BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 3.05 (-0.33)

BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 3.05 (-0.33)

BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 3.05 (-0.33)

BioCryst to Present at Barclays Healthcare Conference
GlobeNewswire - Wed Mar 09, 8:29AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the Barclays Healthcare Conference in Miami, FL on Thursday, March 17, 2016 at 1:05 pm. Eastern Time.
BCRX: 3.05 (-0.33)

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 15.5%
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 7:15AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose almost 16% in the last trading session.
BCRX: 3.05 (-0.33), EARS: 3.27 (-0.13)

Traders Get Bullish on Shares of BioCryst Pharmaceuticals, Shares Up 18.8% (BCRX)
Comtex SmarTrend(R) - Mon Mar 07, 10:18AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 18.8% to $3.07 on 1.5x average daily volume. BioCryst Pharmaceuticals has traded 2.8 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (18.8% to the Dow's 0.1%) and outperformed the S&P 500 (18.8% to the S&P's -0.2%) during today's trading.
BCRX: 3.05 (-0.33)

Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
GlobeNewswire - Mon Mar 07, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice infected with Zika virus will be presented at a World Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland.
BCRX: 3.05 (-0.33)

Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 3.05 (-0.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), CTIC: 0.43 (-0.01), REGN: 372.03 (-9.05)

BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 3.05 (-0.33), PETX: 6.70 (-0.40)

Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 85.92 (-1.15), BCRX: 3.05 (-0.33), DO: 24.32 (-1.16), CNA: 32.12 (-0.06)

Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Tue Feb 09, 8:11AM CST
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $1.78 on volume of 9.3 million shares, above average daily volume of 761,000. BioCryst Pharmaceuticals (NASDAQ:BCRX) has potential upside of 812.9% based on a current price of $1.78 and analysts' consensus price target of $16.25. The stock should find initial resistance at its 50-day moving average (MA) of $8.86 and further resistance at its 200-day MA of $11.16.
BCRX: 3.05 (-0.33)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 3.05 (-0.33)

Shares of BCRX Down 20.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 05, 10:49AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 4 weeks, BioCryst Pharmaceuticals has returned 20.91% as of today's recent price of $6.51.
BCRX: 3.05 (-0.33)

WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.
INO: 10.62 (-0.39), BCRX: 3.05 (-0.33), CMRX: 4.14 (-0.44), XON: 25.27 (+0.14)

16.4% Return Seen to Date on SmarTrend BioCryst Pharmaceuticals Call (BCRX)
Comtex SmarTrend(R) - Fri Jan 29, 10:19AM CST
SmarTrend identified a Downtrend for BioCryst Pharmaceuticals (NASDAQ:BCRX) on January 11th, 2016 at $8.23. In approximately 3 weeks, BioCryst Pharmaceuticals has returned 16.40% as of today's recent price of $6.88.
BCRX: 3.05 (-0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TransDigm Surges Ahead with Strong Q4 and FY Results

TransDigm's Impressive Performance in Fiscal 2026 Here's a company that's really kicking it up a notch—TransDigm Group (NYSE:TDG) just reported some solid fourth-quarter numbers that scream growth. Net sales soared to $2,988 million, marking a 23% hike from last year's fourth quarter of $2,437 million. That's a cool $551 million leap, quite the party for shareholders....

Ebix Relaunches A.D.A.M. SmartCare Platform for Clinicians

Revolutionizing Patient Education with SmartCare When you're in the thick of things, juggling a half-dozen patients with different needs all in a day’s work, you want your tools to be as fast and straightforward as a greasy spoon diner breakfast—simple, satisfying, and utterly dependable. And Ebix is betting they've cooked up just the recipe for that with their...

HSF Opens Scholar Program to All Ethnicities

By Hannah Lewis Updated Nov 10, 2026 Category News Views 339

Redefining Eligibility for Inclusive Progress Picture this: the landscape of educational support shifting towards inclusivity. The Hispanic Scholarship Fund (HSF), long a champion for Hispanic educational advancement, is taking a bold step by opening its doors wider. From January 2027, the HSF Scholar Program will embrace students of all backgrounds, a massive leap away...

Hansa Bolsters Financials with SERB Deal, Eyes Growth

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Ampace Showcases Safety-First Battery Tech for AI Data Centers

PU200's Debut: Making Safety and Space Work in Tandem Ever noticed how safety's become the name of the game for data center operations? Powered by the influx of AI, these digital fortresses crave robust power backup, and Ampace’s stepping in with their PU200 UPS battery solution at Data Centre World Paris 2026. Showing off at Hall 5, Booth M65, Ampace's bringing to the...

Entenmann's Packs Seasonal Joy into Limited-Time Treats

Winter Treats Stepping into the Limelight Another year, another holiday season descended upon us—the calorie indulgence is real, folks. There’s something criminally comforting about these recurring flavors, especially when Entenmann’s and Little Bites decide it’s time to drop some trademark nostalgia into the frosty mix. Pop these limited-edition sweets on your...

Wood Partners Commences on 301-Unit Alta Meadowlands

Planting the Seeds for Alta Meadowlands It's all systems go for Wood Partners and GrayCo as they kick off construction on Alta Meadowlands in Hillsborough, North Carolina. Now, this isn't just another boxy warehouse masquerading as an apartment complex. We're talking a real commitment to shaking up the local real estate scene—a 301-unit community right in the...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

AEWIN Unveils Powerful Servers with AMD EPYC Chips

AEWIN's Bold Move in Server Tech Hang onto your hats, folks, 'cause AEWIN Technologies just took its server game to a whole new level. During the AMD in Depth: EPYC "Venice" event in Las Vegas, AEWIN, nestled neatly under the Qisda Group umbrella, hit the market with hardware that's bound to turn heads—both literally and figuratively. With their latest server offerings...

MIT Study: Reinforced Masonry Slashes Hurricane Damage

Building Smarter: Concrete vs. The Storm Hurricanes are nature’s wrecking balls, and if there’s one thing the latest MIT study tosses on the table, it’s that reinforced concrete masonry isn't just holding its ground—it's changing the game. You see, when Hurricane Irma swung through Florida, it left a clear message written in the rubble: smarter building means...